It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Altered hepatic glucose fluxes are critical during the pathogenesis of type 2 diabetes. G protein-coupled receptors represent important regulators of hepatic glucose production. Recent studies have shown that hepatocytes express GPCRs that can couple to G12/13, a subfamily of heterotrimeric G proteins that has attracted relatively little attention in the past. Here we show, by analyzing several mutant mouse strains, that selective activation of hepatocyte G12/13 signaling leads to pronounced hyperglycemia and that this effect involves the stimulation of the ROCK1-JNK signaling cascade. Using both mouse and human hepatocytes, we also show that activation of endogenous sphingosine-1-phosphate type 1 receptors strongly promotes glucose release in a G12/13-dependent fashion. Studies with human liver samples indicate that hepatic GNA12 (encoding Gα12) expression levels positively correlate with indices of insulin resistance and impaired glucose homeostasis, consistent with a potential pathophysiological role of enhanced hepatic G12/13 signaling.
Altered hepatic glucose fluxes play a key role in the pathogenesis of type 2 diabetes. Here, Pittala et al. show that activation of G12/13 signaling in hepatocytes enhances hepatic glucose production, leading to greatly increased blood glucose levels.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 NIH, Molecular Signaling Section, Laboratory of Bioorganic Chemistry, NIDDK, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
2 Beth Israel Deaconess Medical Center and Harvard Medical School, Division of Endocrinology, Diabetes, and Metabolism, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547)
3 University of Massachusetts Chan Medical School, Program in Molecular Medicine, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
4 NIH, Liver & Energy Metabolism Section, Liver Diseases Branch, NIDDK, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165)
5 Vanderbilt University School of Medicine Basic Sciences, Departments of Molecular Physiology and Biophysics, Nashville, USA (GRID:grid.152326.1) (ISNI:0000 0001 2264 7217)
6 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033)